



Emergent BioSolutions Announces Management Promotions

March 22, 2007

ROCKVILLE, Md.--(BUSINESS WIRE)--March 22, 2007--Emergent BioSolutions Inc. (NYSE: EBS) announced today the promotion of a number of key executives to positions of expanded responsibility to support the company's global business development strategies and manufacturing initiatives.

"I am very pleased to announce today's senior management promotions," said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions Inc. "These promotions mark an important step in our continuing growth plans, and I am confident that the industry expertise, commitment to success and leadership skills of these executives will contribute greatly to the strategic and global development of our company."

Specifics of the management changes, which will become effective on April 1, 2007, include:

- Daniel J. Abdun-Nabi is being promoted to president of Emergent BioSolutions, overseeing a majority of the company's corporate functions. Mr. Abdun-Nabi was formerly senior vice president and general counsel for the company.
- Robert G. Kramer, Sr., is being promoted to executive vice president manufacturing operations, with responsibility for global manufacturing, reporting directly to Edward J. Arcuri, Ph.D., the company's chief operating officer. Mr. Kramer will also continue as president of Emergent Biodefense Operations Lansing.
- Denise Esposito is being promoted to senior vice president and general counsel. Ms. Esposito was formerly vice president and deputy general counsel for the company.
- Mauro Gibellini is being promoted to senior vice president corporate development. Mr. Gibellini was formerly vice president corporate development for the company.

In addition, the company announced that Steven N. Chatfield will be joining the Health Protection Agency (HPA) in the UK in the Fall of 2007. Dr. Chatfield, who will remain with Emergent BioSolutions on a full time basis through August 2007, has held dual roles as chief scientific officer and president, Emergent Product Development UK, since June 2004. The company is recruiting for a new chief scientific officer.

"It is with regret that I leave Emergent BioSolutions but it is a great privilege to be offered the opportunity to join the HPA, an organization that is central to protecting the public health in the UK," said Dr. Steven N. Chatfield. "I have spent my career developing products and strategies to improve public health and this will give me the opportunity to continue my work in the context of public health protection in the UK. I have had an incredibly rich set of experiences during my tenure at Emergent BioSolutions and have benefited immensely from my time working with Fuad and the entire management team. I look forward to spending the next few months ensuring a smooth transition and will be leaving the company with the utmost confidence in its continued development success."

"Steve Chatfield's contributions to our company's success have been substantial," Mr. El-Hibri said. "Under Steve's leadership, significant strides have been made in the development of our commercial product portfolio. He has built a seasoned team of highly skilled professionals with both management and product development expertise. We look forward to working with Steve over the coming months to ensure a smooth transition and wish him continued success upon joining HPA later this year."

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics, consisting of vaccines and therapeutics that induce or assist the body's immune system to prevent or treat disease. The company's biodefense business is focused on immunobiotics for use against biological agents that are potential weapons of bioterrorism. The company's commercial business is focused on development, manufacture and commercialization of immunobiotics for use against infectious diseases. These immunobiotics are designed to address significant unmet or underserved public health needs. More information on the company is available at www.emergentbiosolutions.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions are forward-looking statements. There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including our performance under existing BioThrax(R) sales contracts with the U.S. government, including the timing of deliveries under these contracts; our ability to obtain new BioThrax sales contracts with the U.S. government; our plans for future sales of BioThrax; our plans to pursue label expansions and improvements for BioThrax; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; our ongoing and planned development programs, preclinical studies and clinical trials; our ability to identify and acquire or in license products and product candidates that satisfy our selection criteria; the potential benefits of our existing collaboration agreements and our ability to enter into selective additional collaboration arrangements; the

timing of and our ability to obtain and maintain regulatory approvals for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property portfolio; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company's Registration Statement on Form S-1 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

CONTACT: Emergent BioSolutions Inc.
Robert G. Burrows, 301-795-1877
Vice President, Corporate Communications
burrowsr@ebsi.com

SOURCE: Emergent BioSolutions Inc.